User profiles for Alasdair MacGowan
Alasdair MacGowanConsultant in Infection , Professor of Antimicrobial Therapeutics , North Bristol NHS Trust … Verified email at nbt.nhs.uk Cited by 20444 |
[HTML][HTML] The global threat of antimicrobial resistance: science for intervention
…, E Liébana, L López-Cerero, A MacGowan… - New microbes and new …, 2015 - Elsevier
In the last decade we have witnessed a dramatic increase in the proportion and absolute
number of bacterial pathogens resistant to multiple antibacterial agents. Multidrug-resistant …
number of bacterial pathogens resistant to multiple antibacterial agents. Multidrug-resistant …
[HTML][HTML] EUCAST expert rules in antimicrobial susceptibility testing
…, DFJ Brown, CG Giske, P Heisig, AP MacGowan… - Clinical microbiology …, 2013 - Elsevier
EUCAST expert rules have been developed to assist clinical microbiologists and describe
actions to be taken in response to specific antimicrobial susceptibility test results. They include …
actions to be taken in response to specific antimicrobial susceptibility test results. They include …
Development of the quinolones
MI Andersson, AP MacGowan - Journal of Antimicrobial …, 2003 - academic.oup.com
Since their discovery in the early 1960s, the quinolone group of antibacterials has generated
considerable clinical and scientific interest. Nalidixic acid, the first quinolone to be …
considerable clinical and scientific interest. Nalidixic acid, the first quinolone to be …
Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines
KN Agwuh, A MacGowan - Journal of Antimicrobial …, 2006 - academic.oup.com
The pharmacokinetics of tetracyclines and glycylcyclines are described in three groups.
Group 1, the oldest group, represented by tetracycline, oxytetracycline, chlortetracycline, …
Group 1, the oldest group, represented by tetracycline, oxytetracycline, chlortetracycline, …
European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
…, FW Goldstein, AP MacGowan… - Journal of …, 2003 - academic.oup.com
… Alasdair P. MacGowan … MacGowan, Johan W. Mouton, Anders Österlund, Arne Rodloff,
Martin Steinbakk, Pavla Urbaskova, Alkiviadis Vatopoulos, European harmonization of MIC …
Martin Steinbakk, Pavla Urbaskova, Alkiviadis Vatopoulos, European harmonization of MIC …
Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides
…, M Wootton, RA Howe, AP MacGowan… - Journal of clinical …, 2001 - Am Soc Microbiol
The sensitivity and specificity of seven methods (agar dilution, broth microdilution, Etest at
0.5 and 2.0 McFarland (McF) inocula, two agar screening methods, and population studies [PS…
0.5 and 2.0 McFarland (McF) inocula, two agar screening methods, and population studies [PS…
Antibiotic treatment of gram-positive bone and joint infections
ESR Darley, AP MacGowan - Journal of antimicrobial …, 2004 - academic.oup.com
Gram-positive organisms, particularly staphylococci and streptococci, are responsible for the
majority of bone and joint infections. Treatment of these infections can be difficult, usually …
majority of bone and joint infections. Treatment of these infections can be difficult, usually …
Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections
AP MacGowan - Journal of Antimicrobial Chemotherapy, 2003 - academic.oup.com
The pharmacokinetics and pharmacodynamics of linezolid have been extensively investigated
in laboratory models, healthy volunteers and patients. Three formulations exist: an …
in laboratory models, healthy volunteers and patients. Three formulations exist: an …
Antibiotic resistance
A MacGowan, E Macnaughton - Medicine, 2017 - Elsevier
Antimicrobial resistance continues to increase while the pipeline for new antibiotic development
is drying up; after only eight decades of antibiotic use, bacterial infections that once …
is drying up; after only eight decades of antibiotic use, bacterial infections that once …
Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective
…, GL Drusano, S Harbarth, A MacGowan… - Drug Resistance …, 2011 - Elsevier
There is a growing need to optimize the use of old and new antibiotics to treat serious as well
as less serious infections. The topic of how to use pharmacokinetic and pharmacodynamic (…
as less serious infections. The topic of how to use pharmacokinetic and pharmacodynamic (…